{"id":"W4387836902","doi":"10.1016/j.annonc.2023.09.556","title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Santé Montérégie; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; London Health Sciences Centre; Western University","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Tolerability; Oncology; Adverse effect; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007343384,0.0003996356,0.000922012,0.0003904592,0.0001133759,0.0006710965,0.0003902103,0.0002799736,0.004456665],"category_scores_gemma":[0.0005699022,0.0001670281,0.0007300865,0.0005528337,0.0001581285,0.0003615287,0.0001766001,0.0007421591,0.0007467801],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000929168,"about_ca_system_score_gemma":0.0008211722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002225609,"about_ca_topic_score_gemma":0.01348072,"domain_scores_codex":[0.9997811,0.00007966776,0.00002230245,0.00002943965,0.00004862381,0.00003895169],"domain_scores_gemma":[0.9997736,0.000065485,0.00006835779,0.0000187223,0.00002644426,0.00004734636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.07156458,0.001849415,0.01712115,0.002724715,0.003065044,0.0002413969,0.00009019054,0.002182532,0.02111045,0.000506016,0.0227253,0.8568192],"study_design_scores_gemma":[0.1866761,0.09707684,0.2750665,0.003003039,0.01817323,0.003464592,0.0003138608,0.004696446,0.01711624,0.001923025,0.3923154,0.0001748093],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7358133,0.212344,0.001278289,0.003721502,0.001250993,0.0009415201,0.01490401,0.0003314649,0.02941491],"genre_scores_gemma":[0.8738632,0.08833038,0.002745369,0.004233164,0.0003696986,0.0004817559,0.02072161,0.0000716826,0.009183093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004456665,"threshold_uncertainty_score":0.01490903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1913055246931296,"score_gpt":0.5132972358923467,"score_spread":0.321991711199217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}